| 产品描述: | CID 2745687 acts as a specific, reversible and competitive GPR35 antagonist with a Ki of 12.8 nM |
| 靶点: |
GPR35;GPR |
| 体外研究: |
For ERK1/2 phosphorylation with 1 μM Pamoic acid as the agonist, the CID 2745687 (CID2745687) Ki is 18 nM. CID 2745687 (CID-2745687) is a potent antagonist in β-arrestin-2 interaction assays only at human GPR35.Using the BRET-based GPR35-β-arrestin-2 interaction assay and an EC80 concentration of Zaprinast (20 μM) as agonist, CID 2745687 behaved as a moderately potent, concentration-dependent antagonist at human GPR35 with pIC50=6.70±0.09. CID 2745687 (pIC50=6.27±0.08) fully reverses the agonist action of Cromolyn disodium |
| 体内研究: |
CID 2745687 (CID2745687; 1 mg/kg; administrated orally every day for the last 4 weeks), a specific GPR35 antagonist, reverses Lodoxamide-mediated anti-fibrotic effects. Animal Model: Six-week-old male C57BL/6 mice Dosage: 1 mg/kg Administration: Oral administration, every day for 4 weeks Result: Inhibited Lodoxamide-mediated protective effects. |
| 参考文献: |
1. Pingwei Zhao, et al. Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol Pharmacol. 2010 Oct;78(4):560-8. 2. Laura Jenkins, et al. Antagonists of GPR35 display high species ortholog selectivity and varying modes of action. J Pharmacol Exp Ther. 2012 Dec;343(3):683-95. 3. Mi-Jeong Kim, et al. Lodoxamide Attenuates Hepatic Fibrosis in Mice: Involvement of GPR35. Biomol Ther (Seoul). 2019 Jun 13;28(1):92-97. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.529 ml |
12.644 ml |
25.289 ml |
| 5 mM |
0.506 ml |
2.529 ml |
5.058 ml |
| 10 mM |
0.253 ml |
1.264 ml |
2.529 ml |
| 50 mM |
0.051 ml |
0.253 ml |
0.506 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |